Arrhythmias and Electrolyte Imbalances as Consequences of Cancer



Both arrhythmias and electrolyte imbalances are rather frequent consequences of cancer itself and of cancer treatments (and their side effects). Arrhythmias may be also a consequence of electrolyte imbalance.


  1. 1.
    O’Neal WT, Lakoski SG, Qureshi W, et al. Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study). Am J Cardiol. 2015;115:1090–4.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Erichsen R, Christiansen CF, Mehnert F, et al. Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case–control study. Intern Emerg Med. 2012;7:431–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Guzzetti S, Costantino G, Sada S, Fundarò C. Colorectal cancer and atrial fibrillation: a case–control study. Am J Med. 2002;112:587–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Onaitis M, D’Amico T, Zhao Y, et al. Risk factors for atrial fibrillation after lung cancer surgery: analysis of the society of thoracic surgeons general thoracic surgery database. Ann Thorac Surg. 2010;90:368–74.CrossRefPubMedGoogle Scholar
  5. 5.
    Ostan R, Lanzarini C, Pini E, et al. Inflammaging and cancer: a challenge for the Mediterranean diet. Nutrients. 2015;7:2589–621.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60:2263–70. Review.CrossRefPubMedGoogle Scholar
  7. 7.
    Guzzetti S, Costantino G, Fundarò C. Systemic inflammation, atrial fibrillation, and cancer. Circulation. 2002;106(9):e40. author reply e40.CrossRefPubMedGoogle Scholar
  8. 8.
    Erichsen R, Christiansen CF, Frøslev T, et al. Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study. Br J Cancer. 2011;105:881–3.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Imperatori A, Mariscalco G, Riganti G, et al. Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study. J Cardiothorac Surg. 2012;7:4.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Cardinale D, Sandri MT, Colombo A, et al. Prevention of atrial fibrillation in high-risk patients undergoing lung cancer surgery: the PRESAGE trial. Ann Surg. 2016;264(2):244–51.Google Scholar
  11. 11.
    Zhang L, Gao S. Systematic review and meta-analysis of atrial fibrillation prophylaxis following lung surgery. J Cardiovasc Pharmacol. 2016;67(4):351–7.Google Scholar
  12. 12.
    January CT, Wann LS, Alpert JS, American College of Cardiology/American Heart Association Task Force on Practice Guidelines, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–76.CrossRefPubMedGoogle Scholar
  13. 13.
    Wellens HJ, Schwartz PJ, Lindemans FW, et al. Risk stratification for sudden cardiac death: current status and challenges for the future. Eur Heart J. 2014;35:1642–51.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Melichar B, Králíčková P, Hyšpler R, et al. Hypomagnesaemia in patients with metastatic colorectal carcinoma treated with cetuximab. Hepatogastroenterology. 2012;59:366–71.PubMedGoogle Scholar
  15. 15.
    Dutta S, Horgan PG, McMillan DC. POSSUM and its related models as predictors of postoperative mortality and morbidity in patients undergoing surgery for gastro-oesophageal cancer: a systematic review. World J Surg. 2010;34:2076–82.CrossRefPubMedGoogle Scholar
  16. 16.
    Filip B, Scarpa M, Cavallin F, et al. Postoperative outcome after oesophagectomy for cancer: nutritional status is the missing ring in the current prognostic scores. Eur J Surg Oncol. 2015;41:787–94.CrossRefPubMedGoogle Scholar
  17. 17.
    Wahr JA, Parks R, Boisvert D, et al. Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. JAMA. 1999;281:2203–10.CrossRefPubMedGoogle Scholar
  18. 18.
    DeCarolis DD, Kim GM, Rector TS, Ishani A. Comparative dose response using the intravenous versus enteral route of administration for potassium replenishment. Intensive Crit Care Nurs. 2016;36:17–23.Google Scholar
  19. 19.
    Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122:S829–61.CrossRefPubMedGoogle Scholar
  20. 20.
    Soar J, Deakin CD, Nolan JP, European Resuscitation Council, et al. European Resuscitation Council guidelines for resuscitation 2005. Section 7. Cardiac arrest in special circumstances. Resuscitation. 2005;67 Suppl 1:S135–70. Review.CrossRefPubMedGoogle Scholar
  21. 21.
    Santarpia L, Koch CA, Sarlis NJ. Hypercalcemia in cancer patients: pathobiology and management. Horm Metab Res. 2010;42:153–64.CrossRefPubMedGoogle Scholar
  22. 22.
    Maier JD, Levine SN. Hypercalcemia in the intensive care unit: a review of pathophysiology, diagnosis, and modern therapy. J Intensive Care Med. 2015;30:235–52.CrossRefPubMedGoogle Scholar
  23. 23.
    Le Grand SB. Modern management of malignant hypercalcemia. Am J Hosp Palliat Care. 2011;28:515–7.CrossRefGoogle Scholar
  24. 24.
    Sabry NA, Habib EE. Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study. Med Oncol. 2011;28:584–90.CrossRefPubMedGoogle Scholar
  25. 25.
    Overgaard-Steensen C, Ring T. Clinical review: practical approach to hyponatraemia and hypernatraemia in critically ill patients. Crit Care. 2013;17:206.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Nagler EV, Vanmassenhove J, Van der Veer SN, Nistor I, Van Biesen W, Webster AC, Vanholder R. Diagnosis and treatment of hyponatremia: a systematic review of clinical practice guidelines and consensus statements. BMC Med. 2014;12:231.CrossRefGoogle Scholar
  27. 27.
    Adrogue HJ, Madias NE. Primary care: hyponatremia. New Engl J Med. 2000;342:1581–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Adrogue HJ, Madias NE. Primary care: hypernatremia. New Engl J Med. 2000;342:1493–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Ye Z, Palazzo JP, Lin L, et al. Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients. J Gastroenterol Hepatol. 2013;28:1469–75.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Mughal T, Ejaz AA, Foringer JR, Coiffier B. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev. 2010;36:164–76.CrossRefPubMedGoogle Scholar
  31. 31.
    Mika D, Ahmad S, Guruvayoorappan C. Tumour lysis syndrome: implications for cancer therapy. Asian Pac J Cancer Prev. 2012;13:3555–60. Review.CrossRefPubMedGoogle Scholar
  32. 32.
    Akoz AG, Yildirim N, Engin H, et al. An unusual case of spontaneous acute tumor lysis syndrome associated with acute lymphoblastic leukemia: a case report and review of the literature. Acta Oncol. 2007;46:1190–2. Review.CrossRefPubMedGoogle Scholar
  33. 33.
    Rasool M, Malik A, Qureshi MS, et al. Development of tumor lysis syndrome (TLS): a potential risk factor in cancer patients receiving anticancer therapy. Bioinformation. 2014;10:703–7.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Darmon M, Vincent F, Camous L, Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique (GRRR-OH), et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br J Haematol. 2013;162:489–97.CrossRefPubMedGoogle Scholar
  35. 35.
    Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3–11. Review.CrossRefPubMedGoogle Scholar
  36. 36.
    Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844–54. Review.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Montesinos P, Lorenzo I, Martín G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93:67–74.CrossRefPubMedGoogle Scholar
  38. 38.
    Weeks AC, Kimple ME. Spontaneous tumor lysis syndrome: a case report and critical evaluation of current diagnostic criteria and optimal treatment regimens. J Investig Med High Impact Case Rep. 2015;3:2324709615603199.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis. 2014;21:18–26.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Malaguarnera G, Giordano M, Malaguarnera M. Rasburicase for the treatment of tumor lysis in hematological malignancies. Expert Rev Hematol. 2012;5:27–38.CrossRefPubMedGoogle Scholar
  41. 41.
    Browning LA, Kruse JA. Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother. 2005;39(11):1932–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Cheuk DK, Chiang AK, Chan GC, Ha SY. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database Syst Rev. 2014;8:CD006945.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Department CardiologyHospital MaurizianoTurinItaly
  2. 2.Division of CardiologyIstituto Nazionale per lo Studio e la Cura dei Tumori’ Fondazione Giovanni Pascale’ - IRCCSNaplesItaly
  3. 3.Cardiology UnitIRCCS CRO-National Cancer InstituteAviano (PN)Italy

Personalised recommendations